trending Market Intelligence /marketintelligence/en/news-insights/trending/ejovt9gue0i-fgoch4tu8q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Novus Therapeutics postpones common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novus Therapeutics postpones common stock offering

Novus Therapeutics Inc. said it will postpone its common stock offering due to market conditions, including valuation sensitivity at the current share price.

The Irvine, Calif.-based company was planning to offer 6 million common shares.

Novus, which develops products for disorders of the ear, nose and throat, said its current cash will be sufficient for several business activities in 2019, including completion of phase 1 trials of its drug OP-02 to treat otitis media, a painful ear infection.

As of June 30, the company had $19.2 million in cash and cash equivalents.